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f hapter I gives a general introduction to the thesis and an overview ofthe clinical, biological,
\-z and genetical aspects of lung cancer taken from literature. Today lung cancer is considered
to be the principai cause of cance r death in both men and women. Despite the recent advances in
understanding lung cancer biology and in the areas of its diagnosis and treatment, overall parient
survival has not improved over the past decade.
Lung cancer can be divided in small cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). In contrast to NSCLC, the initial sensitivity of SCLC to therapy is generally high.
SCLC patients with apparently complete responses still harbour disseminated, therapy-resisrant
tumor cells which Í:unction as dormant seed for later clinical relapses leading almost certainly to
the death of the patient. Nevertheless, this particular stage of minimal residual disease (MRD)
represents a promising time point for new adjuvant approaches such as antibody mediated therapl,
since favourable antibody to targ€t cell ratios can be achieved that might allow destruction of the-
se last few but deadly tumor cells.
Hybridoma technology for the production of monoclonal antibodies has provided a method
for the production of specific molecular probes for the analysis of (lung) tumor cells. The identi-
fication and characterization of the recognized tumor-associated antigens (TAA) is important for
studying tumor cell biology and also, since these antigens are obvious targets, for tumor diagnosis
and tumor-speciÊc therapy.
The related epithelial glycoproteins EGP-1 (47.8-kDa) and EGP-2 (38-kDa) are pancarcino-
ma associated antigens that are abundantly expressed on the cell surfaces of various human carci-
nomas including lung cancer. Anti-EGP-2 MAbs, including our MAb MOC3 l, have been stu-
died in diagnostic and therapeutic approaches in cancer. At this moment also an anti-Ë,GP-1
MAb (RS7-3G11) is under cl inical investigation.
Although many hundreds of patients have been experimentally treated with anti-EGP-2
murine MAbs, the immunological and functional aspects of the recognlzed EGP-2 protein are
only poorly understood. The main focus of this thesis is the further characterization of EGP-1
and EGP-2 proteins with respect to the epitopes recognized by the current anti-EGP MAbs and
the elucidation ofthe biological function ofthese proteins.
Furthermore, chapter 1 discusses the need for new antibody mediated therapies in cancer and
recapitulates novel advancements in using antibodies as a building blocks to design more potent








rg cancer is considered
the recent advances in
rtment, overall patient
-small cell lung cancer
:apy is generally high.
ated, therapy-resistant
ng almost certainly to
ridual disease (MRD)
ibody mediated therapy
ow destruction of the-
as provided a merhod
mor cells. The identi-
IAA) is important for
:s, for tumor diagnosis
-kDa) are pancarcino-
:various human carci-
)C31, have been stu-
t also an anri-EGP-1
ted with anti-EGP-2
:d EGP-2 protein are
rcterizarion of EGP- I
anti-EGP MAbs and
rerapies in cancer and
o design more potent
5umttarl
Chapter l l
Chapter II is dedicated to immunologicai and functional analysis of the UBElL gene pro-
duct. Allelic losses in human lung cancer occur most consistently in the 3p2l region. A gene
designated UBElL, recently isolated from this region, appeared to be expressed in normal adult
lung but was found to be consistently and speciÊcally not expressed in a variery oflung cancer
cell lines as assessed by Northern blot analysis. The virtual absence of UBEIL mRNA expression
in human lung cancer may imply a role in the development of this malignancy and it has been
suggested that the UBElL is a class Il tumor suppressor gene. This chapter is aiming at the char-
acterization ofprotein predicted from the presence ofthis gene.
The predicted amino acid sequence of UBEI L is to a large degree similar to the well-known
ubiquitin-activating enzyme E1, which is a key enzyme of the ubiquitin system. This system is
operative in a variety of eukaryotic cell functions, including the degradation of abnormal and
short-lived proteins like nuciear oncoproteins, chromatin (de)condensation, cell cycle progres-
sion, and DNA repair. As a first step to detect and characterize this new protein we used a puri-
Ê'ed E.coli-expressed recombinant UBElL protein fragment and an UBElL sequence-deduced
synthetic oligopeptide coupled to KLH, to generare UBEIL-specific antibodies. Immunoblot
analysis with these antibodies dete cted the UBE I L gene product as a single I 12-kDa protein pre-
sent in normal cells and non-lung cancer cell lines but absent in all human lung cancer cell lines
analyzed thus confirming the data obtained from the expression analysis at a mRNA level.
Immunocytological staining showed that the UBEIL protein can be present in both the nucleus
and the cytoplasm, the relative abundance within these comparrmenrs varying from cell to ceil.
To assess a possible role of this gene in lung tumor cell biology, we reintroduced UBE1L
expression in a small cell lung cancer cell line using an UBEIL eukaryotic expression consrrucr.
Apparent alterations in rhe cancer cell phenorype could however not be observed.
Chapter l l l
Attempts by several laboratories, including our own, to develop antibodies specifically recog-
nizing SCLC cells have resulted in the isolation of very large number of monoclonal antibodies
(MAbs). To introduce some order in the description of the antigens recognized by anti-SCLC
MAbs, workshops on lung cancer antigens were held. In chapter 3 we identiÊed a large number
MAbs with reportedly similar reactivities (SCLC cluster 2 MAbs) to recognize rhe transmembrane
glycoprotein EGP-2 using EGP-2 transfectant cells as a specific substrare. This finding demon-
strated that EGP-2 is a very immunodominant molecule in mice. This chapter also reports on the
newly deÊned SCLC Cluster 1 3 antigen EGP- 1 re cognized by the MAb RS7-3G I 1 . \We identified
the MAbs RS7-3G11, MR23, MR54, and MR110 to be reactive with EGP-1 transfectanrs. \ íe
proposed to call the antigen cletected by SCLC Cluster 2 antibodies: the epithelial glycoprotein 2
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chapter VIII
(EGP-2) and the antigen recogniz€d by Cluster 13 antibodies EGP-1. A short overview of the
characteristics of both proteins and the applications of anti-EGP-2 antibodies is presented in this
chapter.
Chapter lV.
Antitumor antibodies have traditionally been made after immunization of mice with whole
tumor cells or tumor extracts. Many anti-EGP-2 MAbs were shown to recognize identical or
overlapping epitopes as was indicated by tVestern blot analysis. Apparently these epitopes are
highly immunodominant in mice. Another common feature of SCLC cluster 2 MAbs is their
inability to detect the matching antigen in Western blot analysis after reducing SDS-PAGE. This
indicates the presence ofa disulfide bond consolidated tertiary structure exposing non-linear epi-
topes. The apparent immunodominance of this domain makes it difÊcult to generate and select
MAbs against othel potentially useful EGP-2 epitopes.
The aim of this chapter was the identification of the immunodominant EGP-2 domain, and
the construction and puriÊcation of a mutant EGP-2 molecule lacking this domain for facilita-
ting the generation of new EGP-2 MAbs.
in this chapter it is described how we r-rsed the polymerase chain reaction (PCR) to generated
a mutant EGP-2 cDNA (6EGP-2) from which the coding sequences of a putative immunodomi-
nant 6-kDa intra-chain ioop structure has been removed. 6EGP-2 expressed in transfected COS-
7 cells was not recognized by any cluster 2 MAb. To generate new anti-EGP-2 antibodies we con-
structed another mutant recombinant EGP-2 protein (AEGP-2) from which additional
domains, irrelevant for antibody generation (signalpeptide, transmembrane, and cytoplasmic
domains) were removed. AEGP-2 was subsequently expressed in a prokaryotic expression system.
Using this approach we isolated a polyclonal anti-EGP-2 serum and the new second generation
anti-EGP-2 MAb 311/1Kl that showed new properties not observed in the traditionally produ-
ced anti-EGP-2 antibodies in that they can recognize EGP-2 in immunoblot analysis even if
PAGE was performed under reducing conditions.
Using this serum and MAb 311/1Kl it was deduced that SCLC cell line GLC-8 expresses
EGP-2 both as a 38-kDa monomer and disulfide-linked 32-kDal6-kDa dimer EGP-2, while
SCLC cell line GLC-28 only expressed monomer EGP-2 form. The relevance of this difference
in EGP-2 processing for tumor cell biology remains to be determined. Unfortunately, MAb
3 1 1 / 1 Kl proved to be not reactive with native EGP-2 (as is discussed in chapter 8). Nevertheless,
the availabiliry of purified recombinant EGP-2 can facilitate the selection of new anti-EGP-2
MAbs with better tumor targeting characte ristics.
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Chapter V is dedicated to elucidation of biological function of the tumor associated antigen
EGP-2. Transfection experiments in which we introduced EGP-2 expression in an EGP-2 nega-
tive SCLC cell line did not reveal clues to the biolor;ical function of this molecule. Alternatively,
we studied its biological function by using a biotinyiated recombinant soluble derivative of EGP-
2 (sEGPbb) as a probe to detect a possible EGP-2 Lgand. Recombinant soluble EGP-2 was con-
structed en subsequently expressed intheAutographa californica nuclear polyhedrosis virus (baculo-
virus) expression system. In \flestern blot analysis the sEGPb'' probe bound to a 30-kDa protein
band in 2 out of 5 of the assessed carcinoma cell lines, suggesting that this band may be an EGP-2
Iigand.
Chapter Vl
Chapter Vl is dedicated to the EGP-I protein, encoded by the G'\733-1 gene, a retroposon
derived from of the EGP-2 founder gene G.L733-2. Although the EGP- 1 encoding gene was cloned
before the EGP-2 gene, its gene product was not identified by antibodies until recendy. In analogy
to the work done on EGP-2 (chapter 5) also EGP-1 was expressed in and isolated from the baculo-
virus system. Milligram amounts of recombinant soluble EGP-1 were purified by its engineered
polyhistidine affiniry tag using IMAC under native conditions. The recombinant EGP-1 protein
now awaits further functional analvsis.
Chapter Vll
The in uiuo application of murine antibodies in humans is limited by the development of
TIAMA responses and the poor penetration capaciry of immunoglobulin molecules in general due
to their relative large size. The application of recombinant DNA technology in antibody produc-
tion has the potential of simplifying the production of human, clinical grade, homogenous antibo-
dies oflimited size that can be ofsubstantial use to trear cancers.
Chapter VII describes selection and characterization of single chain Fv fragments specific for
EGP-2 from two large human synthetic phage-antibody display libraries. Antibody display on fila-
mentous bacteriophage represents a source of immunological reagents not biased by an animal
immunological environment. The phage display libraries were panned for phage antibodies (Phabs)
with binding specificiry for EGP-2 using either a synthetic EGP-2 peptide or an IMAC purified
prokaryotically expressed truncated EGP-2 molecule (AEGP-2, described in chapter 4). After repe-
ated rounds of selection, phages were identified that showed specific reactiviry with their selective
antigen in phage ELISA. The functional capacity of the monoclonal Phabs was assessed by both
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chapter VIII
FACS analysis and by immuno-histochemistry of tissue specimens, small cell lung cancer (SCLC)
cell lines, and EGP-2 transfectants. Unfortunately, the selected Phabs showed no reaciviry wirh
native EGP-2 as expressed in SCLC tissue specimens or SCLC cell lines. Epitope mapping of the
selected Phabs was performed with an ELISA of overlapping synthetic pepddes that covered the
entire extracellular EGP-2 domain. For Phab 83 a peptide was identified that contained the recog-
nized epitope. Apparently, this epitope is inaccessible on the native EGP-2 molecule, but becomes
exposed upon overexpression ofEGP-2 in transfectants.
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